Reportedly, Takeda and Eli Lilly lost bid to have judge throw out recent $9Bil jury verdict.
Lawsuit Settlement News Reports Actos Drug Cases Trial and Settlement News Update
Sept. 23, 2014
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates pharmaceutical litigation and lawsuit settlement news, announced today a primary focus on assisting plaintiffs of the aftereffects of the pharmaceutical drug Actos. According to court documents on August 28th, U.S. District Judge Rebecca Doherty, the judge who is overseeing thousands of Actos lawsuits, refused to overturn a $9 billion verdict in the first bellwether trial of the proceedings. According to KWQC News in Davenport, IA, the judge ruled against the bid because the jury on the case studied and considered evidence suggesting the officials at Takeda Pharmaceuticals and Eli Lilly knew that the use of Actos could lead to an increased risk in developing bladder cancer but failed to adequately warn both doctors and patients of the possibility. The verdict, which is likely to be reduced on appeal according to legal experts due to its sheer size, is the second-largest in the U.S. in 2014, according to data compiled by Bloomberg. Court documents show the case at hand was the first of over 3,000 Actos lawsuits pending in the Western District of Louisiana to go to trial. All of the pending claims in Louisiana allege that Takeda and other defendants hid the risk of bladder cancer associated with the extended use of the drug. Chris Janish, CEO of MTS, commented on the recent verdicts, “Unfortunately for Eli Lilly and Takeda, the successful sales with this drug clearly produced a high percentage of bladder cancer victims according to the data and the mass lawsuits. The fact that the judge did not throw the verdict out, in spite of a rare $9Bil jury award, says that the case will now proceed to appeal process and will most likely be reduced due to the excessive nature in the message the jury sent to the Actos drug maker.” Originally posted on marketwatch.com by PRNewswire